Group launches seven-figure ad buy boosting vulnerable Democrats on drug prices

Group launches seven-figure ad buy boosting vulnerable Democrats on drug prices
© iStock

A Democratic group is launching $2 million in new digital ads highlighting vulnerable House Democrats’ efforts to lower drug prices. 

The ads from the group Protect Our Care illustrate how Democrats are seeking to keep their momentum going on health care after they focused on the issue in winning back the House last year.

ADVERTISEMENT
The ad buy shows that even as the impeachment inquiry into President TrumpDonald TrumpJan. 6 committee chair says panel will issue a 'good number' of additional subpoenas Overnight Defense & National Security — Presented by AM General — Pentagon officials prepare for grilling Biden nominates head of Africa CDC to lead global AIDS response MORE gains focus, Democrats are still trying to focus on kitchen-table issues like lowering drug prices. 

The new spending will bring the ads to 10 new districts of House freshmen, on top of the 10 districts that were part of an earlier $2 million buy in September focused on pre-existing conditions. 

“Rep. Elissa SlotkinElissa SlotkinWHIP LIST: How House Democrats say they'll vote on infrastructure bill The Hill's Morning Report - Presented by Alibaba - House Democrats plagued by Biden agenda troubles Hoyer tells Israel removal of Iron Dome funding is 'technical postponement' MORE is standing up to big drug companies,” the narrator in the ad for Slotkin, a Michigan Democrat, states. “She’s fighting to give Medicare the power to negotiate with drug companies for lower prices, reducing your costs by as much as 55 percent.”

“Thank her for leading the fight to lower your drug prices,” it adds.

The 10 new districts in the campaign are those of Democratic Reps. Angie Craig (Minn.), Sharice DavidsSharice DavidsNorth Dakota Republican latest House breakthrough COVID-19 case Texas House Republican tests positive for coronavirus in latest breakthrough case Katie Hill launches effort to protect Democratic majority in House MORE (Kan.), Antonio DelgadoAntonio Ramon DelgadoBusiness groups create new headache for Pelosi Chamber of Commerce warns moderate Democrats against voting for reconciliation Six takeaways: What the FEC reports tell us about the midterm elections MORE (N.Y.), Lizzie Fletcher (Texas), Jared Golden (Maine), Susie LeeSuzanne (Susie) Kelley LeeMORE (Nev.), Elaine LuriaElaine Goodman LuriaBusiness groups create new headache for Pelosi Chamber of Commerce warns moderate Democrats against voting for reconciliation GOP ramps up pressure on vulnerable Democrats in spending fight MORE (Va.), Lucy McBathLucia (Lucy) Kay McBathKatie Hill launches effort to protect Democratic majority in House Anti-abortion group targets Democrats ahead of 2022 Moderates revolt on infrastructure in new challenge for Pelosi MORE (Ga.), Chris PappasChristopher (Chris) Charles PappasOvernight Energy & Environment — Democrats detail clean electricity program Scott Brown's wife files to run for Congress New Hampshire Republican Matt Mowers jumps into key House race, setting up 2020 rematch MORE (N.H.) and Susan WildSusan WildLawmakers say Biden must do more on global vaccines Katie Hill launches effort to protect Democratic majority in House Medicare should be able to negotiate drug prices — congressional leaders to allow it MORE (Pa.), all of whom face potentially tough reelection races next year. 

House Democrats are planning to vote next month on their signature legislation to lower drug prices, known as H.R. 3, which would empower the secretary of Health and Human Services to negotiate lower prices for up to 250 drugs per year. 

Speaker Nancy PelosiNancy PelosiManchin cast doubt on deal this week for .5T spending bill Obama says US 'desperately needs' Biden legislation ahead of key votes Congress shows signs of movement on stalled Biden agenda MORE’s (D-Calif.) office has expressed hope that Trump would back the legislation, given his support for Medicare negotiating drug prices during the 2016 campaign. But Trump backed off that support in office, and the White House has recently criticized Pelosi’s bill, in favor of a somewhat more modest bipartisan measure to lower drug prices in the Senate. 

Republicans warn Pelosi’s bill would hinder the development of new cures. 

“We don’t see that happening,” Protect Our Care Chair Leslie Dach said of GOP support for the bill.

“Every statement from the president is that he opposes it,” he added. 

Campaigning on the issue could still prove effective for Democrats given the priority the public places on lowering drug prices. 

Dach said the ads are to “be sure [House Democrats] get thanked and be sure their constituents know they’re doing it.”